Press Release: Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin to Leave the Company

Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin to Leave the Company MADISON, N.J., April 27 -- Wyeth today announced that Chief Financial Officer (CFO) and Vice Chairman Kenneth J. Martin has announced plans to leave the Company at the end of June to pursue personal interests. Mr. Martin joined the Company in 1984 and has served as Chief Financial Officer since 2000. Wyeth plans to name a new CFO in advance of Mr. Martin's departure. "Ken Martin has played key roles at Wyeth for many years and has been an important contributor to our success," says Robert Essner, Chairman and Chief Executive Officer, Wyeth. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.